سعر تيكافير 0.05مجم/مل محلول بالفم 210 مل 2022

Entecavir 0.05 mg/ml entecavir oral solution, 210 ml bottle, by Eva pharma; nucleoside analogue antiviral for chronic hepatitis B.

• Chronic HBV infection in adults with compensated liver disease and evidence of active viral replication, persistently elevated ALT and histological inflammation and/or fibrosisPopulation: AdultsEuropean Medicines Agency (EPAR product information)
• Chronic HBV infection in adults with decompensated liver diseasePopulation: AdultsEuropean Medicines Agency (EPAR product information)
• Chronic HBV infection in nucleoside-naive paediatric patients aged 2 to <18 years with compensated liver diseasePopulation: Paediatric 2 to <18 yearsEuropean Medicines Agency (EPAR product information)

• Most common: headache (9%), fatigue (6%), dizziness (4%) and nausea (3%); also insomnia, somnolence, vomiting, diarrhoea, dyspepsia, increased transaminases; uncommon rash and alopecia; rare anaphylactoid reaction.International label, same formulation · European Medicines Agency (EPAR product information)

• Hypersensitivity to entecavir or to any of the excipients.International label, same formulation · European Medicines Agency (EPAR product information)

• Severe acute exacerbations of hepatitis B can occur on treatment and after discontinuation; monitor liver function closely after stopping.International label, same formulation · European Medicines Agency (EPAR product information)
• Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with nucleoside analogues; patients with decompensated liver disease may be at higher risk.International label, same formulation · European Medicines Agency (EPAR product information)
• Not evaluated in HIV/HBV co-infected patients not receiving antiretroviral therapy; risk of HIV resistance.International label, same formulation · European Medicines Agency (EPAR product information)

• No adequate data in pregnant women; animal studies showed reproductive toxicity at high doses. Should not be used in pregnancy unless clearly necessary; women of childbearing potential should use effective contraception.International label, same formulation · European Medicines Agency (EPAR product information)
• Unknown whether excreted in human milk (excreted in animal milk); breast-feeding should be discontinued during treatment.International label, same formulation · European Medicines Agency (EPAR product information)

• Entecavir: Guanosine nucleoside analogue; the triphosphate competes with deoxyguanosine triphosphate and inhibits HBV polymerase base priming, reverse transcription of the negative strand and positive-strand HBV DNA synthesis.